search
Back to results

Feasibility Controlled Trial of Tibial Nerve Stimulation for Stroke Related Urinary Incontinence (TREAT-UI)

Primary Purpose

Stroke, Urinary Incontinence

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
NeuroTrac continence stimulators
NeuroTrac continence stimulators
Sponsored by
Glasgow Caledonian University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke focused on measuring transcutaneous posterior tibial nerve stimulation, Randomised controlled trial, Feasibility

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men or women aged ≥ 18 years, with a diagnosis of stroke based on the WHO criteria (WHO 1989) and stroke-related urinary incontinence of at least once weekly.
  • Onset of stroke ≥ 4 weeks previously and discharged from hospital to own home following a new stroke episode within the previous 6 months.
  • Physically, cognitively and communicatively able and willing to learn to apply TPTNS or has carer who is able and willing to learn.

Exclusion Criteria:

  • Pre-existing urinary incontinence prior to stroke.
  • Current Urinary Tract Infection.
  • Voiding dysfunction requiring intermittent/indwelling catheterisation.
  • Cardiac pacemaker in situ.
  • Concurrent neurological diagnosis eg dementia, Multiple Sclerosis, diabetic neuropathy.
  • Reduced/absent sensation at electrode placement sites.
  • Post-void residual urine volume of > 150ml.

Sites / Locations

  • NHS Ayrshire and Arran
  • NHS Lanarkshire

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

TPTNS

Sham TPTNS

Arm Description

12 stimulation sessions of 30 minutes duration, delivered twice weekly over a 6 week period using a NeuroTrac continence stimulator. Two surface electrodes are applied to the non-hemiparetic ankle, where appropriate, or the right ankle where no hemiparesis exists. The electrical stimulator is pre-programmed to safely deliver 30 minutes of continuous stimulation with a pulse frequency of 10 hertz and pulse width 200µs22. The intensity of the current will depend on the stroke survivor's perception threshold and individual comfort and is self-adjusted at each session, but will normally range between 15 and 40 milliamps.

The sham stimulation group will self- or carer-deliver a similar programme of twelve, 30 minute sessions twice weekly for 6 weeks NeuroTrac continence stimulator. The surface electrodes will be positioned on the lateral malleolar area of the ankle, not the medial aspect, to avoid the posterior tibial nerve. The stimulation intensity will be increased until sensation is reported, then turned down to 4mA for the 30 minute session, ensuring that despite avoiding the posterior tibial nerve, there is no therapeutic stimulation provided.

Outcomes

Primary Outcome Measures

Frequency of reported episodes of urinary incontinence as a measure of effectiveness.
Positive response to International Consultation on Incontinence Questionnaire-Urinary Incontinence Short-Form (ICIQ-UI SF). This outcome will be the primary outcome for a future full evaluation trial, should it prove feasible.

Secondary Outcome Measures

Changes in the severity of urinary incontinence episodes experienced.
Number of participants with adverse events as a measure of safety and tolerability.
Changes in severity of urinary urgency, frequency and nocturia.
By completion of AUASI
Urinary symptoms experienced on the American Urological Association Symptom Index
Mean Urgency Perception Scores recorded on a 3 day bladder diary
Patient Perception of Bladder Condition
Severity of bowel symptoms
Patient Perception of Bowel Condition
Changes in post-void residual urine volume.
Amount of urine leakage in 24 hours
Participants perception of independence from any help with activities of daily living
Measured by completion of the Barthel Index Score and Modified Rankin Score.

Full Information

First Posted
August 12, 2014
Last Updated
May 25, 2016
Sponsor
Glasgow Caledonian University
Collaborators
The Stroke Association, United Kingdom, University of Central Lancashire, Nursing, Midwifery & Allied Health Professions Research Unit, NHS Greater Glasgow and Clyde, NHS Lanarkshire
search

1. Study Identification

Unique Protocol Identification Number
NCT02239796
Brief Title
Feasibility Controlled Trial of Tibial Nerve Stimulation for Stroke Related Urinary Incontinence
Acronym
TREAT-UI
Official Title
A Feasibility Study for a Randomised Controlled Trial of Transcutaneous Posterior Tibial Nerve Stimulation to Alleviate Stroke-related Urinary Incontinence.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Glasgow Caledonian University
Collaborators
The Stroke Association, United Kingdom, University of Central Lancashire, Nursing, Midwifery & Allied Health Professions Research Unit, NHS Greater Glasgow and Clyde, NHS Lanarkshire

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To aim of this study is to establish the feasibility of undertaking a phase III trial of transcutaneous posterior tibial nerve electrical stimulation (TPTNS) to alleviate stroke-related urinary incontinence.
Detailed Description
Stroke-related urinary incontinence (UI) persists in more than one third of stroke survivors. It is associated with significant burden including reduced quality of life, increased morbidity and disability. Urgency UI, together with overactive bladder (OAB) symptoms (frequency, urgency, nocturia), is most commonly experienced. Current continence care is limited to lifestyle advice and behavioural interventions such as voiding programmes. There is a reliance on containment approaches and a lack of available options for active treatment. Intermittent electrical stimulation of the posterior tibial nerve (TPTNS) is effective for treating non-stroke neurogenic UI and OAB, but has not been tested in the stroke population. This pilot randomised controlled trial (RCT) aims to test the potential effectiveness of TPTNS for stroke-related bladder dysfunction. Adults with stroke-related UI will be randomised to TPTNS or sham. They and/or their carer will be taught to self-deliver a programme of TPTNS over a six week period. Bladder function, associated healthcare costs and quality of life outcomes will be measured at 6, 12 and 26 weeks. A nested process evaluation will be conducted. Pilot RCT and process evaluation results will inform the design of a phase III RCT of TPTNS to treat urinary incontinence in the stroke population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Urinary Incontinence
Keywords
transcutaneous posterior tibial nerve stimulation, Randomised controlled trial, Feasibility

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
54 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TPTNS
Arm Type
Experimental
Arm Description
12 stimulation sessions of 30 minutes duration, delivered twice weekly over a 6 week period using a NeuroTrac continence stimulator. Two surface electrodes are applied to the non-hemiparetic ankle, where appropriate, or the right ankle where no hemiparesis exists. The electrical stimulator is pre-programmed to safely deliver 30 minutes of continuous stimulation with a pulse frequency of 10 hertz and pulse width 200µs22. The intensity of the current will depend on the stroke survivor's perception threshold and individual comfort and is self-adjusted at each session, but will normally range between 15 and 40 milliamps.
Arm Title
Sham TPTNS
Arm Type
Sham Comparator
Arm Description
The sham stimulation group will self- or carer-deliver a similar programme of twelve, 30 minute sessions twice weekly for 6 weeks NeuroTrac continence stimulator. The surface electrodes will be positioned on the lateral malleolar area of the ankle, not the medial aspect, to avoid the posterior tibial nerve. The stimulation intensity will be increased until sensation is reported, then turned down to 4mA for the 30 minute session, ensuring that despite avoiding the posterior tibial nerve, there is no therapeutic stimulation provided.
Intervention Type
Device
Intervention Name(s)
NeuroTrac continence stimulators
Intervention Description
Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact. Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators.
Intervention Type
Device
Intervention Name(s)
NeuroTrac continence stimulators
Intervention Description
We are using NeuroTrac continence stimulators.
Primary Outcome Measure Information:
Title
Frequency of reported episodes of urinary incontinence as a measure of effectiveness.
Description
Positive response to International Consultation on Incontinence Questionnaire-Urinary Incontinence Short-Form (ICIQ-UI SF). This outcome will be the primary outcome for a future full evaluation trial, should it prove feasible.
Time Frame
Up to 16 months
Secondary Outcome Measure Information:
Title
Changes in the severity of urinary incontinence episodes experienced.
Time Frame
Up to 16 months
Title
Number of participants with adverse events as a measure of safety and tolerability.
Time Frame
Up to 16 months
Title
Changes in severity of urinary urgency, frequency and nocturia.
Description
By completion of AUASI
Time Frame
Up to 16 months
Title
Urinary symptoms experienced on the American Urological Association Symptom Index
Time Frame
Up to 16 months
Title
Mean Urgency Perception Scores recorded on a 3 day bladder diary
Time Frame
Up to 16 months
Title
Patient Perception of Bladder Condition
Time Frame
Up to 16 months
Title
Severity of bowel symptoms
Time Frame
Up to 16 months
Title
Patient Perception of Bowel Condition
Time Frame
up to 16 months
Title
Changes in post-void residual urine volume.
Time Frame
Up to 16 months
Title
Amount of urine leakage in 24 hours
Time Frame
Up to 16 months
Title
Participants perception of independence from any help with activities of daily living
Description
Measured by completion of the Barthel Index Score and Modified Rankin Score.
Time Frame
Up to 16 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men or women aged ≥ 18 years, with a diagnosis of stroke based on the WHO criteria (WHO 1989) and stroke-related urinary incontinence of at least once weekly. Onset of stroke ≥ 4 weeks previously and discharged from hospital to own home following a new stroke episode within the previous 6 months. Physically, cognitively and communicatively able and willing to learn to apply TPTNS or has carer who is able and willing to learn. Exclusion Criteria: Pre-existing urinary incontinence prior to stroke. Current Urinary Tract Infection. Voiding dysfunction requiring intermittent/indwelling catheterisation. Cardiac pacemaker in situ. Concurrent neurological diagnosis eg dementia, Multiple Sclerosis, diabetic neuropathy. Reduced/absent sensation at electrode placement sites. Post-void residual urine volume of > 150ml.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joanne Booth
Organizational Affiliation
Glasgow Caledonian University
Official's Role
Principal Investigator
Facility Information:
Facility Name
NHS Ayrshire and Arran
City
Ayrshire
Country
United Kingdom
Facility Name
NHS Lanarkshire
City
Glasgow
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Feasibility Controlled Trial of Tibial Nerve Stimulation for Stroke Related Urinary Incontinence

We'll reach out to this number within 24 hrs